Proactive Investors - Run By Investors For Investors

Collagen Solutions inks significant manufacturing deal for wound-healing product

Jamal Rushdy, chief executive of Collagen Solutions PLC (LON:COS), discusses with Proactive Investors a manufacturing agreement that's been reached for the Excellagen product with Olaregen Therapeutix - a New York-based firm focused on products in the wound care market.

Collagen will manufacture Excellagen for Olaregen following a deal signed in September 2018 between the latter and US biotechnology firm Gene Biotherapeutics, for whom Collagen originally made the product and assisted in its development.

Excellagen is designed to treat wounds that are often complex and difficult to heal such as diabetic foot ulcers, burns, and venous (leg) or pressure ulcers among others.

 
Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full COS profile View Profile

Collagen Solutions PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use